Table 1.
Baseline Characteristics of the Study Population
| Characteristic | n = 1253 |
| Mean age (SD), y | 57.4 (10.1) |
| Mean BMI (SD), kg/m2 | 28.7 (6.2) |
| Mean ALT (SD), U/L | 65.6 (62) |
| Mean AST (SD), U/L | 63.2 (48.9) |
| Male, No. (%) | 801 (63.9) |
| Ethnicity, No. (%) | |
| African American/black | 673 (53.7) |
| Caucasian | 387 (30.9) |
| Hispanic | 157 (12.5) |
| Other | 36 (2.9) |
| Insurance, No. (%) | |
| Medicaid/Medicaid Managed Care | 455 (36.3) |
| Medicare Part D Plan | 374 (29.8) |
| Private (commercial) insurance | 330 (26.3) |
| No insurance | 57 (4.5) |
| Other/unknown | 37 (3) |
| Born between 1945–1965 (baby boomer), No. (%) | 928 (74.1) |
| HIV coinfection, No. (%) | 225 (18) |
| HBV coinfection, No. (%) | 16 (1.3) |
| Diabetes mellitus, No. (%) | 303 (24.2) |
| History of solid organ transplantation, No. (%) | 90 (7.2) |
| Documentation of psychiatric illness, No. (%) | 420 (33.5) |
| Hepatocellular carcinoma, No. (%) | 49 (3.9) |
| Treatment-naïve, No. (%) | 1022 (81.6) |
| Drug–drug interactions present at baseline, No. (%) | 596 (47.6) |
| On dialysis, No. (%) | 38 (3) |
| Genotype, No. (%) | |
| 1 | 1108 (88.4) |
| 1A | 779 (70.3)a |
| 1B | 299 (27)a |
| Not otherwise specified | 30 (2.7)a |
| 2 | 57 (4.5) |
| 3 | 66 (5.3) |
| 4 | 12 (1) |
| 6 | 6 (0.5) |
| Other | 4 (0.3) |
| METAVIR score, No. (%) | |
| Noncirrhotic, not otherwise staged | 73 (5.8) |
| F0 | 103 (8.2) |
| F1 | 131 (10.5) |
| F2 | 217 (17.3) |
| F3 | 224 (17.9) |
| F4 | 505 (40.3) |
| CTP class A | 418 (82.8)b |
| CTP class B | 69 (13.7)b |
| CTP class C | 18 (3.6)b |
| Regimen, No. (%) | |
| SOF + SMV | 110 (8.8) |
| SOF + SMV + RBV | 1 (0.1) |
| LDV/SOF | 697 (55.6) |
| LDV/SOF + RBV | 60 (4.8) |
| PrOD | 4 (0.3) |
| PrOD + RBV | 12 (1) |
| DCV + SOF | 26 (2.1) |
| DCV + SOF + RBV | 6 (0.5) |
| EBR/GZR | 107 (8.5) |
| EBR/GZR + RBV | 7 (0.6) |
| SOF/VEL | 114 (9.1) |
| SOF/VEL + RBV | 17 (1.4) |
| SOF/VEL/VOX | 13 (1) |
| G/P | 79 (6.3) |
| Length of therapy, No. (%) | |
| 8 wk | 113 (9) |
| 12 wk | 1050 (83.8) |
| 16 wk | 6 (0.5) |
| 24 wk | 84 (6.7) |
| History of alcohol use in last 6–12 mo, No. (%)c | |
| No | 846 (67.5) |
| Yes | 390 (31.1) |
| History of IVDU in last 6–12 mo, No. (%)c | |
| No | 1120 (89.4) |
| Yes | 70 (5.6) |
| History of IVDU ever, No. (%)c | |
| No | 541 (43.2) |
| Yes | 539 (43) |
| History of other illicit substance use in last 6–12 mo, No. (%)c | |
| No | 1022 (81.6) |
| Yes | 199 (15.9) |
| History of other illicit substance use ever, No. (%)c | |
| No | 429 (34.2) |
| Yes | 648 (51.7) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh; DCV, daclatasvir; DDI, drug–drug interaction; EBR, elbasvir; G/P, glecaprevir/pibrentasvir; GZR, grazoprevir; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IVDU, intravenous drug use; LDV, ledipasvir; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response; VEL, velpatasvir; VOX, voxilaprevir.
aPercentages based on number of genotype 1 patients.
bPercentages based on number of F4 patients.
cPercentages do not sum to 100% due to missing data.